Biotech catalyst calendar: clinical trial readouts

$29 one-time

A calendar of clinical trial readouts for publicly traded drug and biotech companies, from the official ClinicalTrials.gov registry. Each trial is linked to its stock ticker. The primary completion date is when the trial's main result is measured, and companies usually announce topline results within weeks to a few months of it.

1,198 upcoming or just-finished Phase 2 and 3 trials from 278 listed companies, including 448 Phase 3 readouts in the next 12 months. In the last 90 days, 2 listed-company trials were terminated, suspended or withdrawn and 7 were delayed. Refreshed every weekday.

What you get

• Catalyst calendar spreadsheet (opens in Excel): ticker, company, drug, condition, phase, patients, status and primary completion date, soonest first
• Trial changes spreadsheet: terminations and suspensions (with the stated reason), completion dates pushed back or pulled forward, results posted and new trials, last 90 days
• Every company-sponsored Phase 1-3 trial we track, listed or private
• PDF report with charts and tables: readouts by month, phase and therapeutic-area pie charts, the companies with the most upcoming readouts, and the next Phase 3 readouts
• A link to every trial's registry page

Columns

primary_completion, estimated, days_away, ticker, company, sponsor, phase, status, drug, conditions, therapeutic_area, enrollment, title, acronym, start_date, study_completion, last_update, nct_id, url

Not investment advice. Data from the ClinicalTrials.gov registry.